Cerevel Therapeutics Inc (CERE) - Multiplikator forward rega marang pendapatan
Cerevel Therapeutics (CERE) develops targeted molecules to combat Alzheimer's and schizophrenia. The brand solidified its status as a reliable clinical leader following its acquisition by a pharma behemoth. High R&D potential is focused on receptor bioengineering for Parkinson's disease. The projected P/S dynamics on the GURU.Markets terminal linear chart visualize the business valuation, where reflects the most recent value of the metric.
Rincian metrik komprehensif lan analitis Cerevel Therapeutics (CERE)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Cerevel Therapeutics|CERE - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal cerevel.com|CERE - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Cerevel Therapeutics|CERE - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Cerevel Therapeutics|Indikator likuiditas cepet cerevel.com
- rincian asil keuangan lan kelipatan valuasi:
CERE - Bathi resik|Bathi mangsa ngarep Cerevel Therapeutics|CERE - Rasio rega pasar marang bathi resik|Pangali Forward P/E cerevel.com|CERE - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Cerevel Therapeutics Inc|CERE - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Cerevel Therapeutics|CERE - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan cerevel.com|CERE - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Cerevel Therapeutics
- statistik dodolan lan pendapatan perusahaan:
Analisis fundamental perusahaan:CERE (Cerevel Therapeutics, Inc.)
The forward P/S ratio assesses the market value of a company relative to its expected revenue, allowing investors to determine the degree of asset overvaluation amid a potential decline in demand. By analyzing the projected P/S multiple, one can evaluate the fair value of Cerevel Therapeutics (CERE), whose diversified development of neuropsychiatric drugs across various trial stages minimizes the risk of capital stagnation while awaiting the commercialization of its pipeline.
Pesaing langsung
Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CeriBell|Multiplikator Forward P/S Prothena Corporation plc|Rasio rega marang prakiraan pendapatan Alector Therapeutics (ALEC)|Annexon Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan omeros.com OMER|neurogene.com (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|acimmune.com - Multiplikator Forward P/S|Voyager Therapeutics Inc (VYGR) - Multiplikator forward rega marang pendapatan|Neumora Corp (NMRA) - Rasio rega marang prakiraan pendapatan|Scilex Holding Company, Inc. (SCLX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TVGN|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alpha Cognition Inc. ACOG|Rasio rega marang prakiraan pendapatan cogrx.com (CGTX)|Rasio kapitalisasi marang dodolan sing dikarepake Inhibikase Therapeutics, Inc.|Multiplikator Forward P/S SAVA (Cassava Sciences Inc)|Multiplikator Forward P/S Assertio Holdings, Inc. ASRT|COYA - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan Vistagen (VTGN)|OVID: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Acumen Pharmaceuticals Inc. (ABOS)|Multiplikator forward rega marang pendapatan CRVO|Kapitalisasi marang prakiraan pendapatan ATHE (Alterity Therapeutics)|Rasio rega marang prakiraan pendapatan Clene Nanomedicine (CLNN)|PEPG (PepGen) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Jupiter Neurosciences Inc JUNS|Rega forward marang dodolan RLMD|ANVS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Grace Therapeutics Inc|AIFF: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Klotho Neurosciences Inc (KLTO)|Rasio rega marang prakiraan pendapatan neurosense-tx.com|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Reviva Pharmaceuticals Holdings Inc. RVPH|Rasio rega marang prakiraan pendapatan MetaVia Inc. (MTVA)|Rasio kapitalisasi marang dodolan sing dikarepake NeurAxis Inc|Multiplikator Forward P/S HSDT (heliusmedical.com)|Rega forward marang dodolan PASG|NEUP: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Minerva Neurosciences Inc|Athira Pharma (ATHA) - Rasio rega marang prakiraan pendapatan|Addex Therapeutics, Ltd. - Rega forward marang dodolan|ALZN (Alzamend Neuro) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep cyclerion.com CYCN|Multiplikator Forward P/S PTIX|KTTA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S CRGT (Cortigent, Inc.)|Avenue Therapeutics Inc (ATXI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BCLI - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep caratherapeutics.com|CHRO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Eliem Therapeutics (ELYM)|ITCI (Intra-Cellular Therapies Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Longboard|Multiplikator Forward P/S MRNS|Rasio kapitalisasi marang dodolan sing dikarepake nkgenbiotech.com|Multiplikator Forward P/S NRBO (neurobopharma.com)|Sage Therapeutics, Inc (SAGE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SNPX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan TRVN (Trevena, Inc)|VIGL: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep anewmeds.com (WENA)
